Literature DB >> 21494901

Alterations in brain metabolism during the first year of HIV infection.

Margaret R Lentz1, Woong-Ki Kim, Hyun Kim, Caroline Soulas, Vallent Lee, Nagagopal Venna, Elkan F Halpern, Eric S Rosenberg, Kenneth Williams, R G González.   

Abstract

Migration of both uninfected and infected monocytes into the brain during acute HIV infection likely initiates metabolic changes that can be observed with magnetic resonance spectroscopy (MRS). Herein, we measured changes in brain metabolism during the first year of HIV infection and examined the relationship of these metabolite levels to CD16+ monocyte populations measured in the blood. MRS was performed on nine HIV+ subjects identified during acute HIV infection and nine seronegative control subjects. HIV+ subjects were examined within 90 days of an indeterminate Western blot, then again 2 and 6 months later, during early infection. Blood samples were collected for plasma viral RNA and monocyte subset quantification. HIV+ subjects were identified with acute viral ailment and did not display severe cognitive deficits such as dementia or minor cognitive motor disorder. Changes in lipid membrane metabolism (choline levels) in the frontal cortex and white matter were observed during the initial year of HIV infection. Greater numbers of CD16+ monocytes were associated with lower N-acetylaspartate levels and higher choline levels in the brain. These results suggest that HIV infection induces metabolic changes in the brain early during infection and that these changes may be related to monocyte dynamics in the periphery.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21494901      PMCID: PMC3753682          DOI: 10.1007/s13365-011-0030-9

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  31 in total

1.  Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy.

Authors:  D Finzi; J Blankson; J D Siliciano; J B Margolick; K Chadwick; T Pierson; K Smith; J Lisziewicz; F Lori; C Flexner; T C Quinn; R E Chaisson; E Rosenberg; B Walker; S Gange; J Gallant; R F Siliciano
Journal:  Nat Med       Date:  1999-05       Impact factor: 53.440

2.  Magnetic resonance imaging and proton magnetic resonance spectroscopy of megalencephaly and dilated Virchow-Robin spaces.

Authors:  Samuel Groeschel; Knut Brockmann; Peter Dechent; Ekkehard Wilichowski; Jens Frahm; Folker Hanefeld
Journal:  Pediatr Neurol       Date:  2006-01       Impact factor: 3.372

3.  Elevated subcortical choline metabolites in cognitively and clinically asymptomatic HIV+ patients.

Authors:  D J Meyerhoff; C Bloomer; V Cardenas; D Norman; M W Weiner; G Fein
Journal:  Neurology       Date:  1999-03-23       Impact factor: 9.910

4.  Highly active antiretroviral therapy reverses brain metabolite abnormalities in mild HIV dementia.

Authors:  L Chang; T Ernst; M Leonido-Yee; M Witt; O Speck; I Walot; E N Miller
Journal:  Neurology       Date:  1999-09-11       Impact factor: 9.910

5.  Monocyte heterogeneity underlying phenotypic changes in monocytes according to SIV disease stage.

Authors:  Woong-Ki Kim; Yue Sun; Hien Do; Patrick Autissier; Elkan F Halpern; Michael Piatak; Jeffrey D Lifson; Tricia H Burdo; Michael S McGrath; Kenneth Williams
Journal:  J Leukoc Biol       Date:  2009-10-20       Impact factor: 4.962

6.  Early viral replication in the brain of SIV-infected rhesus monkeys.

Authors:  L Chakrabarti; M Hurtrel; M A Maire; R Vazeux; D Dormont; L Montagnier; B Hurtrel
Journal:  Am J Pathol       Date:  1991-12       Impact factor: 4.307

7.  In vivo 1H MRS of brain injury and repair during acute SIV infection in the macaque model of neuroAIDS.

Authors:  Jane B Greco; Susan V Westmoreland; Eva M Ratai; Margaret R Lentz; Ken Sakaie; Julian He; Prabhat K Sehgal; Eliezer Masliah; Andrew A Lackner; R Gilberto González
Journal:  Magn Reson Med       Date:  2004-06       Impact factor: 4.668

8.  Longitudinal analysis of clinical markers following antiretroviral therapy initiated during acute or early HIV type 1 infection.

Authors:  Sigall Kassutto; Kaveh Maghsoudi; Mary N Johnston; Gregory K Robbins; Nicole C Burgett; Paul E Sax; Daniel Cohen; Eunice Pae; Ben Davis; Kimon Zachary; Nesli Basgoz; Erika M C D'agata; Victor DeGruttola; Bruce D Walker; Eric S Rosenberg
Journal:  Clin Infect Dis       Date:  2006-02-27       Impact factor: 9.079

9.  Resting cerebral blood flow: a potential biomarker of the effects of HIV in the brain.

Authors:  B M Ances; D Sisti; F Vaida; C L Liang; O Leontiev; J E Perthen; R B Buxton; D Benson; D M Smith; S J Little; D D Richman; D J Moore; R J Ellis
Journal:  Neurology       Date:  2009-09-01       Impact factor: 9.910

10.  In vivo proton magnetic resonance spectroscopy reveals region specific metabolic responses to SIV infection in the macaque brain.

Authors:  Eva-Maria Ratai; Sarah J Pilkenton; Jane B Greco; Margaret R Lentz; Jeffrey P Bombardier; Katherine W Turk; Julian He; Chan-Gyu Joo; Vallent Lee; Susan Westmoreland; Elkan Halpern; Andrew A Lackner; R Gilberto González
Journal:  BMC Neurosci       Date:  2009-06-22       Impact factor: 3.288

View more
  43 in total

1.  Two patterns of cerebral metabolite abnormalities are detected on proton magnetic resonance spectroscopy in HIV-infected subjects commencing antiretroviral therapy.

Authors:  Alan Winston; Chris Duncombe; Patrick C K Li; John M Gill; Stephen J Kerr; Rebekah L Puls; Simon D Taylor-Robinson; Sean Emery; David A Cooper
Journal:  Neuroradiology       Date:  2012-07-07       Impact factor: 2.804

2.  The role of neuroplasticity and cognitive reserve in aging with HIV: recommendations for cognitive protection and rehabilitation.

Authors:  David E Vance; Pariya L Fazeli; Joan S Grant; Larry Z Slater; James L Raper
Journal:  J Neurosci Nurs       Date:  2013-10       Impact factor: 1.230

3.  Quantitative MRI Measures in SIV-Infected Macaque Brains.

Authors:  Xiaodong Zhang; Chunxia Li
Journal:  J Clin Cell Immunol       Date:  2013

4.  Treatment of HIV in the CNS: effects of antiretroviral therapy and the promise of non-antiretroviral therapeutics.

Authors:  Michael J Peluso; Serena Spudich
Journal:  Curr HIV/AIDS Rep       Date:  2014-09       Impact factor: 5.071

5.  Cerebral metabolite changes prior to and after antiretroviral therapy in primary HIV infection.

Authors:  Andrew C Young; Constantin T Yiannoutsos; Manu Hegde; Evelyn Lee; Julia Peterson; Rudy Walter; Richard W Price; Dieter J Meyerhoff; Serena Spudich
Journal:  Neurology       Date:  2014-09-26       Impact factor: 9.910

6.  Cognitive Consequences of Aging with HIV: Implications for Neuroplasticity and Rehabilitation.

Authors:  David E Vance; Graham J McDougall; Natalie Wilson; Marcus Otavio Debiasi; Shameka L Cody
Journal:  Top Geriatr Rehabil       Date:  2014-01

7.  Substance use is a risk factor for neurocognitive deficits and neuropsychiatric distress in acute and early HIV infection.

Authors:  Erica Weber; Erin E Morgan; Jennifer E Iudicello; Kaitlin Blackstone; Igor Grant; Ronald J Ellis; Scott L Letendre; Susan Little; Sheldon Morris; Davey M Smith; David J Moore; Steven Paul Woods
Journal:  J Neurovirol       Date:  2012-12-19       Impact factor: 2.643

8.  A comparison of two post-processing analysis methods to quantify cerebral metabolites measured via proton magnetic resonance spectroscopy in HIV disease.

Authors:  Joseph Scott; Jonathan Underwood; Lucy J Garvey; Borja Mora-Peris; Alan Winston
Journal:  Br J Radiol       Date:  2016       Impact factor: 3.039

9.  Can Speed of Processing Training Ameliorate Depressive Symptomatology in Adults with HIV?

Authors:  David E Vance; Shameka C Humphrey; William C Nicholson; Rita Jablonski-Jaudon
Journal:  Ann Depress Anxiety       Date:  2014-09-04

10.  Neuronal-Glia Markers by Magnetic Resonance Spectroscopy in HIV Before and After Combination Antiretroviral Therapy.

Authors:  Napapon Sailasuta; Jintanat Ananworanich; Sukalaya Lerdlum; Pasiri Sithinamsuwan; James L K Fletcher; Somporn Tipsuk; Mantana Pothisri; Tanate Jadwattanakul; Supunnee Jirajariyavej; Thep Chalermchai; Stephanie Catella; Edgar Busovaca; Akash Desai; Robert Paul; Victor Valcour
Journal:  J Acquir Immune Defic Syndr       Date:  2016-01-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.